All In Biotech

Drug Trial Radar · NCT01178073

A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

Last checked: Nov 20, 2026Latest source record: Sep 13, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 610 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

610

Actual

Start

Oct 1, 2010

Primary completion

Jul 31, 2014

Study completion Jul 31, 2014

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
Collaborators
Gilead Sciences
First posted
Aug 9, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the two treatment strategies; first-line combination therapy (ambrisentan and tadalafil) versus first-line monotherapy (ambrisentan or tadalafil) in subjects with Pulmonary Arterial Hypertension. This will be assessed by time to the first clinical failure event.

Conditions

  • Hypertension, Pulmonary

Interventions

  • ambrisentanDrug

    ambrisentan (target dose: 10mg)

  • tadalafilDrug

    tadalafil (target dose: 40mg)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With First Adjudicated Clinical Failure (CF) Event, Death, Hospitalisation for Worsening PAH, Disease Progression, Unsatisfactory Long-term Clinical Response, All Through FAVTime frame: From Baseline up to the Final Assessment Visit (FAV) (average of 609 days)

Locations

143 sites in 14 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Mobile, Alabama

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Tucson, Arizona

  • GSK Investigational Site

    La Jolla, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Sacramento, California

  • GSK Investigational Site

    Torrance, California

  • GSK Investigational Site

    Aurora, Colorado

  • GSK Investigational Site

    Gainesville, Florida

  • GSK Investigational Site

    Jacksonville, Florida

  • GSK Investigational Site

    Kissimmee, Florida

  • GSK Investigational Site

    Orlando, Florida

  • GSK Investigational Site

    Weston, Florida

  • GSK Investigational Site

    Atlanta, Georgia

  • GSK Investigational Site

    Decatur, Georgia

  • GSK Investigational Site

    Oakbrook Terrace, Illinois

  • GSK Investigational Site

    Carmel, Indiana

  • GSK Investigational Site

    Iowa City, Iowa

  • GSK Investigational Site

    Kansas City, Kansas

  • GSK Investigational Site

    New Orleans, Louisiana

  • GSK Investigational Site

    Portland, Maine

  • GSK Investigational Site

    Baltimore, Maryland

  • GSK Investigational Site

    Boston, Massachusetts

  • GSK Investigational Site

    Boston, Massachusetts

  • GSK Investigational Site

    Boston, Massachusetts

  • GSK Investigational Site

    Springfield, Massachusetts

  • GSK Investigational Site

    Ann Arbor, Michigan

  • GSK Investigational Site

    Detroit, Michigan

  • GSK Investigational Site

    Troy, Michigan

  • GSK Investigational Site

    St Louis, Missouri

  • GSK Investigational Site

    Omaha, Nebraska

  • GSK Investigational Site

    Morristown, New Jersey

  • GSK Investigational Site

    Newark, New Jersey

  • GSK Investigational Site

    New Hyde Park, New York

  • GSK Investigational Site

    New York, New York

  • GSK Investigational Site

    New York, New York

  • GSK Investigational Site

    New York, New York

  • GSK Investigational Site

    New York, New York

  • GSK Investigational Site

    Rochester, New York

Showing 40 of 143 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.